KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Long-Term Deferred Tax (2025)

Aurinia Pharmaceuticals' Long-Term Deferred Tax history spans 1 years, with the latest figure at $176.2 million for Q4 2025.

  • For Q4 2025, Long-Term Deferred Tax changed N/A year-over-year to $176.2 million; the TTM value through Dec 2025 reached $176.2 million, changed N/A, while the annual FY2025 figure was $176.2 million, N/A changed from the prior year.
  • Long-Term Deferred Tax reached $176.2 million in Q4 2025 per AUPH's latest filing.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $176.2 million in Q4 2025 to a low of $176.2 million in Q4 2025.